Research programme: antibody-drug conjugates - Advanced Proteome Therapeutics/ Heidelberg Pharma

Drug Profile

Research programme: antibody-drug conjugates - Advanced Proteome Therapeutics/ Heidelberg Pharma

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator Advanced Proteome Therapeutics; Heidelberg Pharma
  • Class Antibacterials; Drug conjugates; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 19 Dec 2016 USPTO issues notice of allowance covering APC's technology involving specific proteins that have been attached (linked) to other proteins and exhibit activity against tumour cells
  • 19 Oct 2016 Advanced Proteome Therapeutics and Toronto Recombinant Antibody Centre enters into an exclusive option agreement to license antibody candidates for development of antibody-drug conjugates for Cancer
  • 18 Oct 2016 Research programme: antibody-drug conjugates - Advanced Proteome Therapeutics/ Heidelberg Pharma is available for licensing as of 13 Oct 2016. http://www.heidelberg-pharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top